LLY Stock Summary and Trading Ideas (Eli Lilly And Company | NYSE:LLY)

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.

As of March 9, 2026, LLY stock price climbed to $1,008.39 with 2,413,644 million shares trading.

LLY has a beta of 0.60, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.05 to the broad based SPY ETF.

LLY has a market cap of $951.27 billion. This is considered a Mega Cap stock.

Last quarter Eli Lilly And Company reported $19 billion in Revenue and $7.54 earnings per share. This beat revenue expectation by $1 billion and exceeded earnings estimates by $.58.

In the last 3 years, LLY traded as high as $1,133.95 and as low as $309.32.

The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, VUG, SPY.

LLY has underperformed the market in the last year with a return of +11.2%, while SPY returned +19.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in LLY shares. However, LLY has outperformed the market in the last 3 month and 2 week periods, returning 0.0% and -0.1%, while SPY returned -0.8% and -1.6%, respectively. This indicates LLY has been having a stronger performance recently.

LLY support price is $967.71 and resistance is $1,012.95 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.